Table 1. Summary of TPC-1 growth on day 4 using combination of CI-1040 and Src inhibitors.

Treatment	Reduction (%)	p value vs mock*	p value vs CI-1040 alone*
1 μM CI-1040	59.7	< 0.001	n/a
0.1 μM PP2	36.2	< 0.001	n/a
1 μM CI-1040 + 0.1 μM PP2	73.1	< 0.001	<0.007
1 μM PP2	71.4	< 0.001	n/a
1 μM CI-1040 + 1 μM PP2	87 1	< 0.001	<0.001
0.1 μM SU6656	29.9	< 0.001	n/a
1 μM CI-1040 + 0.1 μM SU6656	68.7	< 0.001	0.01
1 μM SU6656	61.4	< 0.001	n/a
1 μM CI-1040 + 1 μM su6656	77.5	< 0.001	<0.001
0.01 μM Dasatinib	36.7	< 0.001	n/a
1 μM CI-1040 + 0.01 μM Dasatinib	74.0	< 0.001	0.001
0.1 μM Dasatinib	69.2	< 0.001	n/a
1 μM CI-1040 + 0.1 μM Dasatinib	84.8	< 0.001	<0.001

^*p value was determined by Student t-test